February 17, 2020
Chugai Pharmaceutical said on February 14 that it has filed its anti-PD-L1 antibody Tecentriq (atezolizumab) in combination with its anti-VEGF antibody Avastin (bevacizumab) for the treatment of unresectable, advanced or metastatic hepatocellular carcinoma (HCC) in Japan. The submission is supported...read more